IP Library Granted Patent US 8,957,048
Granted Patent B2
US 8,957,048 · App. 13/645,035 · Granted Feb 17, 2015

Compositions for the treatment of dry eye

Inventors: Joseph G. Vehige (Laguna Niguel, CA); Peter A. Simmons (Yorba Linda, CA)
Assignee: Allergan, Inc.
A61K31/745A61K9/0048A61K47/10A61K47/26A61K47/32A61K47/38A61K31/205A61K33/22A61K36/47A61K31/047A61K31/34A61K31/717
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,957,048
App. No.
13/645,035
Granted
Feb 17, 2015
Kind
B2
Abstract

The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.

Claims (20)

1. An ophthalmic composition consisting of polyoxyethylene (20) sorbitan monooleate, carboxymethylcellulose sodium, glycerin, boric acid, acrylates/C10-30 alkyl acrylate crosspolymer, castor oil, erythritol, levocarnitine, sodium hydroxide, and water.

2. The composition of claim 1 , wherein the polyoxyethylene (20) sorbitan monooleate is present at a concentration of about 0.1% w/w to about 2% w/w.

3. The composition of claim 1 wherein the carboxymethylcellulose sodium is present at a concentration of about 0.1% w/w to about 2% w/w.

4. The composition of claim 1 , wherein the glycerin is present at a concentration of about 0.2% w/w to about 5% w/w.

5. The composition of claim 1 , wherein the acrylates/C10-30 alkyl acrylate crosspolymer is present at a concentration of about 0.02% to about 0.5% w/w.

6. The composition of claim 1 , wherein the castor oil is present at a concentration of about 0.05% to about 0.5% w/w.

7. The composition of claim 1 , wherein the erythritol is present at a concentration of about 0.05% or about 3% w/w: and the levocarnitine is present at a concentration of about 0.05% or about 3% w/w.

8. The composition of claim 1 , consisting of about 0.5% w/w polyoxyethylene (20) sorbitan monooleate, about 0.5% w/w carboxymethylcellulose sodium, about 1.0% w/w glycerin, about 0.6% w/w boric acid, about 0.1% w/w acrylates/C10-30 alkyl acrylate crosspolymer, about 0.25% w/w castor oil, about 0.25% w/w erythritol, about 0.25% w/w levocarnitine, sodium hydroxide, a pH of about 7.3 and water.

9. A method of treating, curing or mitigating dry eye syndrome comprising administering an effective amount of an ophthalmic composition according to claim 1 to an eye of a man or other animal in need thereof.

10. An ophthalmic composition consisting of polyoxyethylene (20) sorbitan monooleate, carboxymethylcellulose sodium, glycerin, boric acid, acrylates/C10-30 alkyl acrylate cross/golymer, castor oil, erythritol, levocarnitine, sodium hydroxide, a stabilized oxychloro complex and water.

11. The composition of claim 10 , wherein the stabilized oxychloro complex is present at a concentration of about 0.002% to about 0.05% w/w.

12. The composition of claim 10 , wherein the polyoxyethylene (20) sorbitan monooleate is present at a concentration of about 0.1% w/w to about 2% w/w.

13. The composition of claim 10 , wherein the carboxymethylcellulose sodium is present at a concentration of about 0.1% w/w to about 2% w/w.

14. The composition of claim 10 , wherein the glycerin is present at a concentration of about 0.2% w/w to about 5% w/w.

15. The composition of claim 10 , wherein the acrylates/C10-30 alkyl acrylate crosspolymer is present at a concentration of about 0.02% to about 0.5% w/w.

16. The composition of claim 10 , wherein the castor oil is present at a concentration of about 0.05% to about 0.5% w/w.

17. The composition of claim 10 , wherein the erythritol is present at a concentration of about 0.05% or about 3% w/w; and the levocarnitine is present at a concentration of about 0.05% or about 3% w/w.

18. The composition of claim 10 , consisting of about 0.5% w/w polyoxyethylene (20) sorbitan monooleate, about 0.5% w/w carboxymethylcellulose sodium, about 1.0% w/w glycerin, about 0.6% w/w boric acid, about 0.1% w/w acrylates/C10-30 alkyl acrylate crosspolymer, about 0.25% w/w castor oil, about 0.25% w/w erythritol, about 0.25% w/w levocarnitine, about 0.01% w/w stabilized oxychloro complex, sodium hydroxide, and water; and wherein the pH of the composition is about 7.3.

19. A method of treating, mitigating or curing dry eye syndrome comprising administering an effective amount of an ophthalmic composition according to claim 10 to an eye of a man or other animal in need thereof.

20. A method of treating, mitigating or curing dry eye syndrome comprising administering an effective amount of an ophthalmic composition according to claim 18 to an eye of a man or other animal in need thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2012
From: VEHIGE, JOSEPH G.; SIMMONS, PETER A.
To: ALLERGAN, INC.
Reel/Frame 029078/0922 →
Continuity (2)
Provisional Application 61544151 · Oct 6, 2011
Related Publication 20130090308A1 · Apr 11, 2013